Trials / Completed
CompletedNCT02553798
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 564 (actual)
- Sponsor
- Journey Medical Corporation · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
Detailed description
Safety will be assessed through adverse events, blood and urine laboratory tests, physical examination, pulse and blood pressure. Local skin reactions will be assessed including burning/stinging, pruritus, edema, erythema, dryness and scaling.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycopyrronium Topical Wipes | Glycopyrronium Topical Wipes |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2015-09-18
- Last updated
- 2021-08-25
- Results posted
- 2018-09-25
Locations
48 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT02553798. Inclusion in this directory is not an endorsement.